- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/54 - Interleukines [IL]
Détention brevets de la classe C07K 14/54
Brevets de cette classe: 4306
Historique des publications depuis 10 ans
|
190
|
256
|
295
|
394
|
438
|
405
|
464
|
473
|
403
|
252
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Immatics Biotechnologies GmbH | 1127 |
124 |
| Regeneron Pharmaceuticals, Inc. | 4786 |
85 |
| Immunitybio, Inc. | 509 |
67 |
| Xencor, Inc. | 411 |
64 |
| Altor BioScience, LLC | 80 |
62 |
| Board of Regents, The University of Texas System | 6141 |
48 |
| The Board of Trustees of the Leland Stanford Junior University | 6687 |
40 |
| The Trustees of the University of Pennsylvania | 4423 |
40 |
| Iovance Biotherapeutics, Inc. | 405 |
40 |
| Modernatx, Inc. | 1281 |
38 |
| Obsidian Therapeutics, Inc. | 80 |
36 |
| Memorial Sloan-Kettering Cancer Center | 2051 |
33 |
| City of Hope | 1041 |
32 |
| National University of Singapore | 2595 |
32 |
| Yale University | 2557 |
32 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3010 |
29 |
| The Regents of the University of California | 20815 |
28 |
| Genentech, Inc. | 4114 |
28 |
| Cytune Pharma | 40 |
26 |
| Takeda Pharmaceutical Company Limited | 2700 |
25 |
| Autres propriétaires | 3397 |